The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016

Article

According to its press release GBI Research has found that the global ophthalmology market will grow at a moderate rate due to the impact of generic erosion in some markets such as glaucoma and allergic conjunctivitis.

According to its press release GBI Research has found that the global ophthalmology market will grow at a moderate rate due to the impact of generic erosion in some markets such as glaucoma and allergic conjunctivitis. However, the unmet need in the macular degeneration and macular edema markets make the ophthalmology market attractive despite generic erosion. The attractiveness of the macular degeneration and macular edema markets is evident from the considerable amount of research and development activity for these indications. The major factor driving the growth of the market is the rising awareness about the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools and an increase in the prevalence of diabetes. The expiry of blockbuster drugs’ patents and increasing pressure from cheap off-label products in some markets will be the key restraints for the market.

Read more here

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.